Study #2018-1064
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients with Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple Myeloma
MD Anderson Study Status
Enrolling
Treatment Agent
TTI-622, Azacitidine, Venetoclax, Carfilzomib, Dexamethasone
Description
Multicenter, open-label, phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in subjects with Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple Myeloma.
Information and next steps
Disease:
Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia
Study phase:
I
Physician name:
Swaminathan Iyer
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.